武汉佰乐博生物技术有限公司
   
     
联系热线
  • 联系人:方经理
  • 电 话:027-65279366
  • 邮箱:products@biolabreagent.com
  • 地 址:武汉市东湖新技术开发区神墩四路666号C栋

恩弗利单抗,Envafolimab, AntibodySystem Laboratories

发表时间:2023-05-09

标题:恩弗利单抗,Envafolimab,CAS: 2102192-68-5AntibodySystem Laboratories

货号:DHJ70104

产品链接:http://www.atagenix.com/product_detail-75183.html

别名:KN-035, CAS: 2102192-68-5

简介:

恩弗利单抗 Envafolimab (ASC 22; KN 035) 是人源化的单域抗 PD-L1 抗体的重组蛋白。Envafolimab 是由抗 PD-L1 结构域与人 IgG1 抗体的 Fc 片段融合而成。Envafolimab 阻断 PD-L1 和 PD-1 之间的相互作用,IC50 值为 5.25?nM。Envafolimab 具有研究实体瘤的潜力。

货号DHJ70104

产品品牌Antibodysystem

通用名Envafolimab

纯度>95% by SDS-PAGE.

浓度1mg/ml

Formulationicon0.01M PBS, pH 7.4.

内毒素Please contact with the lab for this information.

别名KN-035

靶点物种Human CD274/PD-L1/B7-H1

种类Chimeric

受体鉴定(VH-CH2-CH3)2

CAS2102192-68-5

存储条件

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

参考文献:

Envafolimab: First Approval. PMID: 35122636
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. PMID: 34154614
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. PMID: 33973293
Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors. PMID: 36124972
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. PMID: 35932387
Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report. PMID: 36874434
Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia. PMID: 36998453
Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers. PMID: 35347438
Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning. PMID: 34259259
Noninvasive Imaging of Tumor PD-L1 Expression Using [99mTc]Tc-Labeled KN035 with SPECT/CT. PMID: 36541699

联系方式
手机:18108604356
微信扫一扫